Ligand Pharmaceuticals Inc. (LGND) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Ligand Pharmaceuticals’s revenue went from $109M in fiscal 2016 to $268M in fiscal 2025, growth of about 10.5% a year.
Net income in fiscal 2025 was $124M, a net margin of 46.4%; the best year in this period was 2019 with $629M.
Over the twelve months to September 30, 2026, revenue was $254M and net income $51M.
Free cash flow was $49M in fiscal 2025 and positive in 9 of the 10 years shown.
The diluted share count fell 3% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $254M | $268M | $167M | $131M | $196M | $242M | $164M | — | $251M | $141M | $109M |
| Gross profit | — | — | — | — | — | — | — | — | $245M | $136M | $103M |
| Operating income | $26M | $41M | -$23M | $12M | $3M | $104M | $38M | $807M | $164M | $68M | $44M |
| Net income | $51M | $124M | -$4M | $52M | -$33M | $57M | -$3M | $629M | $143M | $13M | -$2M |
| EPS (diluted) | $2.49 | $6.13 | $-0.22 | $2.94 | $-1.98 | $3.31 | $-0.18 | $31.85 | $5.96 | $0.53 | $-0.08 |
| R&D | $23M | $81M | $21M | $25M | $36M | $32M | $41M | $56M | $28M | $27M | $21M |
| Revenue growth | — | +60.4% | +27.3% | −33.1% | −18.8% | +47.7% | — | — | +78.2% | +29.5% | — |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $91M | $49M | $97M | $50M | $138M | $79M | $55M | -$29M | $194M | $89M | $61M |
| Capital spending | -$405000 | -$452000 | -$2M | -$4M | -$18M | -$9M | -$4M | -$3M | -$887000 | -$2M | -$2M |
| Free cash flow | $91M | $49M | $95M | $46M | $120M | $70M | $50M | -$32M | $193M | $86M | $59M |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | $60M | $15M | $0 | $0 | $0 | $0 | $78M | $453M | $123M | $2M | $4M |
| Stock-based pay | $57M | $47M | $41M | $26M | $60M | $39M | $31M | $25M | $21M | $25M | $19M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $734M | $256M | $170M | $212M | $341M | $411M | $1.1B | $718M | $202M | $141M |
| Debt | — | $451M | $7M | $6M | $11M | $338M | $450M | $650M | $610M | $225M | $213M |
| Equity | — | $1.0B | $830M | $701M | $597M | $821M | $710M | $767M | $561M | $400M | $341M |
| Total assets | — | $1.6B | $942M | $787M | $763M | $1.3B | $1.4B | $1.5B | $1.3B | $671M | $602M |
| Shares (diluted) | 20M | 20M | 18M | 18M | 17M | 17M | 17M | 20M | 24M | 23M | 21M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — | — | — | 97.5% | 96.2% | 94.9% |
| Operating margin | 10.1% | 15.3% | -13.5% | 9.1% | 1.6% | 43.0% | 22.9% | — | 65.1% | 48.2% | 40.3% |
| Net margin | 20.3% | 46.4% | -2.4% | 39.7% | -17.0% | 23.7% | -1.8% | — | 57.0% | 8.9% | -1.5% |
| FCF margin | 35.7% | 18.2% | 57.0% | 35.1% | 61.1% | 29.0% | 30.6% | — | 76.8% | 61.2% | 54.0% |
| ROIC | — | 2.2% | -2.1% | 1.4% | 0.4% | 7.1% | 2.6% | 45.0% | 11.6% | 8.6% | 6.3% |
| ROE | — | 12.2% | -0.5% | 7.4% | -5.6% | 7.0% | -0.4% | 82.0% | 25.6% | 3.1% | -0.5% |
Frequently asked questions
What is Ligand Pharmaceuticals’s annual revenue?
$268M in fiscal 2025 and $254M over the twelve months to September 30, 2026.
How much profit does Ligand Pharmaceuticals make?
Net income was $124M in fiscal 2025 (net margin 46.4%).
Is Ligand Pharmaceuticals’s revenue growing?
Yes: revenue rose 60.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.